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INTRODUCTION 
Aging is associated with a metabolic decline characterized by the 
development of changes in fat distribution, obesity, insulin resistance, decrease 
in elasticity, large artery thickening and stiffness as well as endothelial 
dysfunction1,2. All these metabolic alterations are associated with a variety of 
age related diseases that subsequently result in increased mortality3. 
It has been recently demonstrated that Leptin, a 16 kDa fat-derived 
peptide, can modulate many of these metabolic alterations characteristic of 
aging4. Leptin is an adipocyte-derived hormone that regulates food intake and 
energy expenditure5. It is believed to be of importance in regulation of body 
weight. Leptin acts on the brain, through specific receptor, to suppress 
synthesis and secretion of neuropeptide Y, the most potent stimulator of food 
intake and through various downstream mechanisms6. 
Serum leptin concentration is found to be associated with Body Mass 
Index (BMI) and more precisely with body fat mass. Mutations in the gene 
encoding Leptin was found to cause obesity in both animals and humans, 
indicating a relation between the leptin gene and obesity, though the frequency 
was less7.  
Leptin has also extra hypothalamic functions and potential sites of 
action that corresponds to the distribution of leptin receptor. In addition to its 
effect on food intake & energy expenditure, a direct effect of leptin on blood 
pressure has recently been reported8,9. High plasma leptin levels act as a 
pathophysiologic trigger of high blood pressure. A highly polymorphic 
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tetranucleotide repeat polymorphism in the 3’ flanking region of the leptin gene 
has been identified. This polymorphism is associated with hypertension 
independent of obesity. Studies have also shown that chronic infusion of leptin 
in rats has resulted in elevated arterial pressure and heart rate10,11. 
Data from animal studies clearly indicate an association between leptin 
and hypertension, but results of human study are less consistent. Whether the 
association is independent of other factors such as insulin, obesity and renin-
angiotensin systems is not known and needs to be investigated.  
The main objective of the present study is to evaluate the association of 
leptin levels with essential hypertension in the non-obese elderly subjects. 
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REVIEW OF LITERATURE 
 Aging is a maturation process. It is thought to have the positive 
component of development and the negative component of decline. The 
changes that occur with aging can be categorized as those that result from 
aging itself and those that result from diseases, lifestyle and exposures12.  
 Usual aging refers to the common complex of diseases and impairments 
that occur in many elderly people. However this complex is hard to define 
because people age very differently. Successful aging refers to a process by 
which deleterious effects are minimized, preserving function until senescence 
makes life impossible.  
DISEASE Vs AGING 
With aging many physiological functions decline. Many of these 
declines are attributed to aging itself, not disease-related. The distinction 
between normal and disease related may be clear or may simply be defined by 
statistical distribution. For example, some degree of glucose intolerance is 
considered part of normal aging, but diabetes, although very common, is 
considered a disease. 
CARDIOVASCULAR PHYSIOLOGY IN AGING 
 With aging, there are changes in the cardiovascular system, which 
results in alterations in cardiovascular physiology. These changes must be 
differentiated from the effects of pathology, such as coronary artery disease 
that occur with increasing frequency as age advances. The changes with age 
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occur in everyone but not necessarily at the same rate, therefore accounting for 
the differences seen in people between chronological age and physiological 
age.  
 With aging, there is decrease in the elasticity and increase in the 
stiffness of the arterial system. This results in increased afterload on left 
ventricle. This results in increase in systolic blood pressure and left ventricular 
hypertrophy as well as other changes in the left ventricular wall that prolongs 
relaxation of the left ventricle in diastole. With fibrosis of the cardiac skeleton, 
there is calcification at the base of the aortic valve and damage to the His 
Bundle as it perforates the right fibrous trigone. Finally there is decreased 
responsiveness to β-adrenergic receptor stimulation, a decreased reactivity to 
baroreceptors and chemoreceptors and an increase in circulating 
catecholamines. These changes set the stage for all diseases seen in elderly.  
 Differences between cardiovascular function in older and younger 
persons have been quantified. However, interactions between age, disease and 
lifestyle are often overlooked. Whether the prevalence of cardiovascular 
disorders such as hypertension, coronary artery disease and heart failure is due 
to an aging process or these disorders merely occur more frequently in elderly 
persons because of a longer exposure to risk is not yet established. 
CHANGES IN CARDIOVASCULAR STRUCTURE DURING AGING 
The Heart  
 A modest increase in left ventricular wall thickness is normal with age; 
an exaggerated increase occurs in persons with hypertension. Other normal age 
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associated changes include enlargement of left atrium and slight enlargement of 
left ventricular cavity and of the cardiac silhouette. 
 The amount of fibrous tissue within the myocardium increases with age 
but does not contribute to cardiac mass, rather myocardial wall thickening 
occurs largely because cardiac myocytes increase in size. Some myocytes are 
replaced by fibrous tissue, so that the number of myocytes decreases with age. 
THE VASCULATURE 
 With age, the walls of large distributing arteries thicken and the arteries 
become dilated and elongated. The thickening results mainly from an increase 
in intimal thickness due to cellular accumulation, matrix deposition and 
fragmentation of internal elastic membrane.  
 Collagen also increases and changes in the cross-linking of collagen in 
vascular media may make it less elastic. Glycoprotein eventually disappears 
from elastin fibrils and elastin becomes frayed. The total MPS content (ground 
substance) of interstitial matrix is unaltered with age but the amount of 
dermatan and heparan sulphate contained in the matrix increases and that of 
hyaluronate and chondroiton sulphate decreases. 
CHANGES IN CARDIOVASCULAR FUNCTION DURING AGING 
Compliance 
 With age, there is reduction in ventricular compliance. 
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Cardiac filling and Preload 
 The early diastolic left ventricular filling rate progressively slows after 
age. This reduction is attributed to structural changes in left ventricular 
myocardium or due to prolonged isovolumic relaxation. But the late diastolic 
filling is greater because the atrial contraction is augmented. The augmented 
contraction is accompanied by atrial enlargement and is manifested as fourth 
heart sound. 
After load 
 After load varies from person to person and depends on peripheral 
vascular resistance, aortic impedance and aortic pulse wave velocity. With age, 
peripheral vascular resistance increases, aortic impedance increases and also 
the pulse wave velocity. As a result pressure waves from peripheral sites are 
returned to heart more quickly. Arterial stiffening and late augmentation of 
systolic blood pressure explains the overall increase in systolic blood pressure 
with age. Also it reflects the resetting of the baroreceptor reflex to a higher 
level. 
Myocardial contractility 
 It involves ionised calcium activation of myofilaments (contraction-
excitation coupling). Age associated changes are related to alterations in gene 
expression. The increase in myoplasmic calcium after excitation at low rates 
and affinity of myofibrils for calcium do not change with age. At higher rates 
of excitation, the amplitude of calcium transient is not well documented. 
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 Relaxation is prolonged in senescent cardiac muscle, because calcium is 
removed more slowly from myoplasm during diastole. This slow removal 
probably occurs because the sarcoplasmic reticulum sequesters less calcium. A 
reduction in myocardial relaxation rate results in less complete myocardial 
relaxation when mitral valve opens and in a increase in early diastolic left 
ventricular filling rate. 
Ejection fraction and Stroke volume 
 The resting ejection fraction is not reduced with age. Resting stroke 
volume increases slightly in older men but remains constant in older women. 
Heart rate 
 The supine resting heart rate does not change, but the heart rate while 
seated decreases slightly in men and women. The intrinsic sinus rate decreases 
significantly with age. 
Cardiac output 
 The resting cardiac index is not reduced in healthy age men. But in older 
women, resting cardiac output decreases slightly because neither end-diastolic 
volume nor stroke volume increases to compensate for the modest reduction in 
heart rate. 
 There is much evidence supporting the hypothesis that age associated 
changes in cardiovascular structure and function are related to the markedly 
increased risk for cardiovascular disease in older persons. Some vascular 
changes that occur with aging are risk factors for an increase in systolic blood 
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pressure and diastolic blood pressure and for the development of 
atherosclerosis and stroke. 
Hypertension 
 Hypertension is very common as age advances. The morbidity and 
mortality of hypertension poses a great challenge globally for the society and 
for the health care professionals. It is the most important modifiable risk factor 
for coronary heart disease, stroke, congestive heart failure, end-stage renal 
disease and peripheral vascular disease. 
 With increasing age of general population, the prevalence of 
hypertension and its complications are likely to increase rather than decrease. 
The detection and treatment of hypertension is therefore, vital in the battle to 
reduce cardiovascular disease and stroke, which are currently the major cause 
of death13. 
Epidemiology 
 Hypertension is an important public health challenge because of its 
commonness and concomitant risks of cardiovascular disease. The estimated 
total number of adults with hypertension in 2000 was 972 million. Of these 333 
million were estimated in economically developed countries and 639 million in 
economically developing countries. Europe – 37.4%, China – 22.6%, Australia 
– 37.4%, Africa – 26.9%, South America – 40.7% and North America – 
37.4%14. 
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Definition 
 The more recent guidelines from the American Joint National 
Committee on prevention, detection, evaluation and treatment of high blood 
pressure (JNC VII)15 define hypertension as a systolic blood pressure of 
140mm Hg and/or a diastolic blood pressure of greater than 90mm Hg. 
 The definition of hypertension is necessarily arbitrary and varies 
between expert groups. However, it can be defined pragmatically as that level 
of blood pressure above which the use of anti-hypertensive treatment does 
more good than harm. This level will vary from patient to patient and balances 
the risks of untreated hypertension with those of long term exposure to anti-
hypertensive drugs and their side effects16. 
Guidelines & Classifications 
 Hypertension is one of the conditions for which disease-specific 
guidelines have been generated by different organizations. The more recent 
guidelines from the American Joint National Committee on prevention, 
detection, evaluation and treatment of high blood pressure (JNC VII) is given 
in Table1. 
Aetiology of hypertension 
 There are two types:  
a. Primary or essential hypertension – over 95% of patients with 
hypertension in whom no immediately obvious underlying 
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causewas present. It is a product of genetic predisposition with 
environmental and lifestyle factors. 
Genetic predisposition – A family history of hypertension, 
heart disease, type2 diabetes mellitus 
Environmental factors – Age, hormone state 
Lifestyle factors – Smoking, heavy drinking, overweight, 
sodium and calorie rich diet, lack of physical activity, 
stress 
b. Secondary hypertension – 2 to 5%; has an underlying cause, 
usually involving the kidneys and the endocrine system 
CAUSES  
1. Endocrine   
Adrenocortical hyperfunction –  
* Cushings’ disease and syndrome 
* Primary hyperaldosteronism 
* Congenital adrenogenital syndrome (17α-
hydroxylase and 11β hydroxylase defects) 
* Myxedema 
* Acromegaly 
2. Pheochromocytoma 
3. Vascular – Coarctation of aorta 
Renal artery stenosis or renal infarction 
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4. Renal 
Intrinsic renal disease (glomerulonephritis) 
Polycystic kidney 
Chronic renal failure 
5. Drugs  Oral contraceptives 
  Sympathomimetics 
COMPLICATIONS OF HYPERTENSION 
a. Stroke – It is the most devastating consequences of hypertension. 
In patients with hypertension, about 80% of strokes are 
ischaemic, caused by intra-arterial thrombosis or embolisation 
from the heart and large arteries. The remaining 20% are from 
haemorrhagic causes, which may also be related to high blood 
pressure15. 
b. Coronary artery disease – Fatal coronary artery disease is seven 
times more common among hypertensives than fatal stroke. 
Controlled trials have consistently shown that stroke and heart 
failure are largely preventable by treatment of high blood 
pressure but the reduction of coronary thrombosis is less 
impressive. Adequate treatment reduces heart attack risk by 
approximately 20%. 
c. Left ventricular hypertrophy – As a result of increased after load 
imposed on the heart by high blood pressure, the mass of left 
ventricular muscle increases. While this is initially a 
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compensatory response, the increased muscle mass outstrips its 
oxygen supply and coupled with the reduced coronary vascular 
reserve seen in hypertension, can result in myocardial ischemia 
even with normal coronary arteries. Thus, left ventricular 
hypertrophy secondary to hypertension is a major risk factor for 
myocardial infarction, stroke, sudden death and congestive 
cardiac failure.  
d. Large vessel arterial disease – Peripheral vascular disease as 
manifested by intermittent claudication is three times more 
common in patients with hypertension. Atheromatous disease in 
the aorta, coupled with hypertension, may progress to aortic 
aneurysm. Extracranial carotid artery disease is also more 
common and is one of the mechanisms by which hypertension 
leads to the increased risk of stroke. 
e. Renal disease – Malignant hypertension frequently leads to 
progressive renal failure. There is some controversy as to whether 
this is also the case in patients with mild to moderate essential 
hypertension. 
f. Retinopathy – Hypertension leads to vascular changes in the eye, 
referred to as hypertensive retinopathy. These changes have been 
classified by Keith, Wagener and Barker into four grades. The 
most severe form – malignant hypertension – is defined clinically 
as raised blood pressure in association with bilateral retinal 
flame-shaped haemorrhages and/or cotton wool spots and/or hard 
exudates with/without papilledema. 
   
13
PATHOGENESIS 
 The pathogenesis of essential hypertension is multifactorial and highly 
complex. Multiple factors modulate the blood pressure for adequate tissue 
perfusion. They include humoral mediators, vascular reactivity, circulating 
blood volume, vascular caliber, blood viscosity, cardiac output, blood vessel 
elasticity and neural stimulation17. Multiple factors have been proposed as 
possible pathogenesis of essential hypertension. They include 
HEREDITY 
 Genetic factors have long been assumed to be involved in the genesis of 
hypertension. Most studies support the concept that the genetic inheritance is 
probably multifactorial or that a number of different genetic defects each have 
an elevated blood pressure as one of their phenotypic expressions. Both 
monogenic defects and susceptibility genes have now been reported which has 
one of their consequences an increased arterial pressure. 
ENVIRONMENT 
 A number of environmental factors including salt intake, obesity, 
alcohol intake, family size all have been assumed to be important in the 
increase in blood pressure with age. 
SALT SENSITIVITY 
 This environmental factor has received the greatest attention. It 
illustrates the heterogeneous nature of the essential hypertensive population, in 
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that the blood pressure is only approximately 60% of hypertensives are 
particularly responsive to the level of sodium intake.  
ROLE OF RENIN 
 Renin is an enzyme secreted by the juxtaglomerular cell of the kidney 
and linked with aldosterone in a negative feedback loop. Its rate of secretion 
depends on the volume status of the individual. The end product of the action 
of renin on its substrate is the generation of angiotensin II. The response of 
target tissues to this peptide is uniquely determined by the prior dietary 
electrolyte intake. 
CELL MEMBRANE DEFECT 
 Generalised cell membrane defect is one possible explanation. This 
hypothesis derives most of its data from studies on circulating blood elements, 
in which abnormalities in the transport of sodium across the cell membrane 
have been documented. This defect occurs in many cells of the body 
particularly the vascular smooth muscle cells, which leads to an abnormal 
accumulation of calcium in the vascular smooth muscle leading to increased 
vascular reactivity. 
INSULIN RESISTANCE 
 Insulin resistance and/or hyper insulinaemia have been suggested to be 
responsible for the increased arterial pressure. Four mechanisms have been 
postulated. 
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a. Insulin has mitogenic action, which increases vascular smooth 
muscle hypertrophy. 
b. It produces renal sodium retention and increases sympathetic 
activity, which increases arterial pressure. 
c. Insulin also modifies ion transport across the cell membrane, 
increasing the cytosolic calcium levels of insulin-sensitive 
vascular or renal tissues. 
Recently studies have demonstrated that high plasma leptin levels are 
associated with high blood pressure in the elderly18. Data from available animal 
studies clearly indicate an association between leptin and hypertension, 
whereas results of human studies are less consistent. There are several possible 
mechanisms, which include 
a. One possible explanation is through sympathetic activation. 
Leptin administered intravenously and intracerebroventricularly 
in rodents has been found to increase the sympathetic outflow to 
kidneys, skeletal muscle vasculature and the neural traffic to the 
adrenal19,20. 
b. It induces endothelin-1, which is a potent vasoconstrictor and 
mitogen21 
c. It promotes angiogenesis, which contributes to the modulation of 
endothelial cell proliferation in atherosclerosis22. 
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d. It increases sodium and water excretion via a direct tubular 
action. But during leptin resistance it produces anti-natriuresis 
leading to hypertension23. 
Diagnosis 
 An accurate measurement of the blood pressure is the key to diagnosis. 
At any given visit, an average of three blood pressure readings taken two 
minutes apart using a mercury manometer is preferable. Blood pressure should 
be measured in both the supine and sitting positions, auscultating with the bell 
of the stethoscope. Improper cuff size may influence blood pressure 
measurement and hence wider cuff is preferable. The patient should rest quietly 
for at least five minutes before the measurement. Palpation of all the peripheral 
pulses should be performed. 
Laboratory studies 
 Unless a secondary cause for hypertension is suspected, only the 
following routine laboratory studies should be performed. 
a. Complete Blood Count, serum electrolytes, serum creatinine, plasma 
glucose, uric acid and urine analysis. 
b. Lipid profile 
c. Electrocardiogram 
Treatment 
 Lifestyle modifications – JNC VII recommendations to lower blood 
pressure and decrease cardiovascular disease risk include the following24-27. 
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• Weight reduction 
• Limit alcohol intake and smoking 
• Increase physical activity 
• Reduce sodium intake to no more than 6 gms 
• Adequate  intake  of  dietary  potassium,  calcium  and  
magnesium 
• Reduce intake of dietary saturated fats and cholesterol 
Initial therapy based on the JNC VII report recommendations is as 
follows 
* Pre-hypertension (systolic –> 120-139, diastolic –> 80-89): No 
anti-hypertensive drug is indicated 
* Stage I hypertension (systolic –> 140-159, diastolic –> 90-99): 
Thiazide-type diuretics are recommended. ACE inhibitor, beta 
blocker, calcium channel blocker or combination may be 
considered 
* Stage II hypertension (systolic > 160, diastolic > 100): Two drug 
combination (Thiazide - type diuretic and ACE inhibitor or beta 
blocker is recommended). 
 
   
18
Prevention 
 A comprehensive strategy for reduction in mortality and morbidity from 
hypertension must include prevention strategies, earlier detection and adequate 
treatment. 
 Even a small reduction in blood pressure confers significant health 
benefits. A 2mm Hg reduction in diastolic pressure is estimated to decrease the 
risk of stroke by 15% and the risk of coronary artery disease by 6%. Prevention 
may be achieved by 
• Weight control 
• Increased physical activity 
• Moderate sodium and alcohol intake 
• Increased potassium intake 
• A dietary pattern rich in fruits and vegetables, low fat meat, fish  
and dairy products  
AN OVERVIEW OF LEPTIN STRUCTURE, GENE AND EXPRESSION 
 Leptin (Greek leptos, “then”) is a small protein that is produced in 
adipocytes. It is a product of gene designated OB (Obese). The gene has 3 
exons separated by 2 introns in both rodents and humans. The coding region of 
the gene is contained in exon 2 & 3 separated by an intron, approximately 2 kb. 
Considine et al28 reported the mRNA of the OB gene is highly expressed in 
adipocytes. This OB mRNA expression is not detected in human pre-
adipocytes but occur following differentiation of 373L1 and 373F, 422A cells 
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from fibroblasts to mature adipocytes as found by Leroy & co-workers29,30. The 
gene is located in Chromosome 6 in mice and Chr.7q.31.3 in humans31. 
 Protein product of OB gene is a 167 amino acid protein with an amino 
terminal secretory signal sequence of 21 amino acids. The signal sequence is 
removed subsequently in the secretory pathway32. Leptin circulates as 146 
amino acid protein. Its secretion is constitutive. There is no storage form33. It is 
a globular protein with a tertiary structure similar to hemopoietic cytokines 
such as interleukin and granulocyte macrophage colony stimulating factor34. 
The size of the adipocyte appears to be the major determinant of ob mRNA, as 
larger cells contain more ob mRNA than smaller cells isolated from the same 
subject35. 
Leptin Receptors 
 Leptin Receptor OB-R belongs to Class I cytokine receptor family and 
atleast six various alternatively spliced forms of leptin receptor mRNA have 
been reported36. The short length OB-Ra receptor is present in all tissues but its 
functional significant activity is not known.  
a. In the central nervous system: OB-Ra receptor is expressed in the 
choroid plexus and this may transport leptin across the blood brain 
barrier to the cerebrospinal fluid37. In choroid plexus, leptin receptor 
consists of 894 amino acids with 22 amino acid secretory signal 
sequence, 23 amino acid transmembrane domain and a short 
cytoplasmic domain of 34 amino acid. 
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A second leptin OB-Rb receptor is found in hypothalamus and is 
identical to that in choroids plexus except that the intracellular 
domain has additional 269 amino acids. The extra cellular domain 
contains Trp-Ser-X-Ser-Trp motifs and the intracellular domain 
contains the Janus Kinase interaction motif and a signal transducer 
and activator of transcription (STAT) motif. OB-Rc and OB-Rd are 
speculated that they transport leptin across the blood brain barrier. 
The soluble OB-Ra receptor functions as a transport protein 
contributing to binding and activation of circulating leptin38,39. 
b. In peripheral organs: The mRNA of several leptin isoforms has been 
found in non-neuronal tissues such as the pancreas, kidney, liver and in 
the reproductive and haematopoietic organs40. Leptin is involved in 
pathways other than energy metabolism as a true pleotropic hormone 
mediating a variety of peripheral action41,42. 
Leptin binding  
Leptin has been found to bind competitively to atleast three serum 
macromolecules with molecular masses of 85, 176, 240kDa in rodents and to 
176 and 240 kDa in humans43. Leptin binding proteins are possibly soluble 
forms of leptin receptors. In non-obese humans, significant endogenous leptin 
is bound when the leptin level increases as in case of obesity free unbound 
leptin spills over into bioactive free protein pool. Recently it has been 
demonstrated that oxidized form of α2 macroglobulin binds competitively with 
leptin44,45. 
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Leptin receptor and signal transduction 
 Leptin is structurally related to cytokines and acts on receptors that 
belong to the cytokine receptor superfamily. Several different leptin receptor 
isoforms exists including a long form (OB-Ri), which is highly expressed in 
hypothalamus46,47. 
 It activates cytokine-like signal transduction via OB-Ri48. Upon leptin 
stimulation, intracellular Janus tyrosine kinases (JAKs) are activated via 
transphosphorylation and phosphorylates tyrosine residues on the long form of 
leptin receptor and on signal transducers and activators of transcription (STAT) 
proteins49. Phosphorylated STAT proteins dimerize and translocates to the 
nucleus to activate gene transcription. Lack of functional leptin in lepob/lepob 
mice or lack of the intracellular domain of OB-Ri in db/db mice produces 
severe obesity50. In addition, leptin receptor activation stimulates both the 
phosphotidyl-inositol-3-kinase (PI3K) and Ras-mitogen activated protein 
kinase (MAPK) signaling pathways, both of which are downstream of JAK51. 
The arcuate nucleus (ARC) of the hypothalamus serves as the leptin 
signaling center. Leptin targets two adjacent pathways within ARC, the 
appetite- stimulating (Orexigenic) pathway mediated by neuropeptide Y and 
agouti-related protein (AgRP) and the appetite-suppressing (anorexigenic) 
pathway mediated by pro-opiomelanocortin via the Ob-Rb form of leptin 
receptor52. When leptin binds to its receptor, a signaling cascade is initiated, 
activating PI3K. This causes a conversion of F-actin to G-actin, which 
subsequently opens K+ATP channels. 
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Leptin resistance 
 Potential mechanism for leptin resistance include defects in transport of 
leptin across the blood brain barrier, defects in leptin signal transduction in 
leptin-receptor expressing neurons in the hypothalamus and antagonism of 
leptins physiologic actions at one or more steps beyond initial leptin-responsive 
neurons. 
 Recently, a new family of cytokine inducible inhibitors of signaling has 
been identified including CIS (Cytokine-inducible sequence), SOCS-1 
(Suppressor of cytokine signaling), SOCS-2 and SOCS-3. CIS and SOCS are 
small proteins having a central SH2 domain and a 40 aminoacid long carboxy 
terminal SOCS box53. The SH2 domain of SOCS is thought to bind to 
phosphorylated tyrosine residues on JAK proteins, while SOCS box plays a 
role in degradation of SOCS proteins54.  
 Leptin specifically induces expression of SOCS-3 mRNA in regions of 
hypothalamus that expresses OB-Ri55. Forced expression of SOCS-3 blocks 
leptin- receptor mediated signal transduction by attenuating leptin- induced 
JAK-2 tyrosine phosphorylation. Thus SOCS-3 plays a major role in negative 
regulation of proximal leptin signal transduction. 
Physiological functions of leptin 
a. Effect on body fat mass 
  Body weight is a simple non- invasive predictor of body fat and caloric 
balance. Quetelet Index / Body Mass Index is a good index of body fat in both 
men and women. 
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     W (Weight in Kg) 
   BMI      =            
     H2 (Height in m)  
 
 Values greater than 30 represent obesity. Other methods for measuring 
body fat mass include Waist / Hip ratio, bio-electric impedance analysis, 
subcutaneous tissue biopsy and skin fold thickness. Serum leptin is highly 
correlated with percent body fat and with BMI in humans56. 
 Leptin is secreted by adipocytes and circulates in the blood in 
concentrations proportional to fat mass content. Interaction of leptin with its 
receptor in the hypothalamus inhibits food intake and increases energy 
expenditure, that leads to a reduction in adipose tissue mass57.  
The mean serum leptin level in normal obese human is approximately 
four fold higher than that detected in healthy lean subjects. Some earlier studies 
have found that leptin level is independent of body fat58. For a given BMI, 
women have leptin concentration approximately twice that of men that remains 
even after correction for percentage body fat. Testosterone is responsible for 
this gender difference59. 
b. Effect on carbohydrate and lipid metabolism 
Leptin directly inhibits intracellular lipid concentrations by reducing 
fatty acid and triglyceride synthesis and concomitantly increasing lipid 
oxidation60. This is mediated by an inhibitory effect of leptin on acetyl-CoA 
carboxylase activity, the rate-limiting enzyme in fatty acid synthesis61. 
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Inhibition of this enzyme leads to a reduction in malonyl-CoA, an inhibitor of 
carnitine acyl transferaseI and mitochondrial β-oxidation. 
Inhibition of acetyl CoA carboxylase will block fatty acid synthesis and 
favours mitochondrial uptake and oxidation, resulting in lower intracellular 
fatty acid and triglyceride concentration. Unger and coworkers suggest that 
leptin, by reversing lipid accumulation in several tissues, could have beneficial 
effects on insulin resistance and β-cell function, ultimately improving glucose 
homeostasis. 
c. Effect on energy balance 
Leptin increases energy expenditure by which it regulates body 
weight62. This involves increased thermogenesis in brown adipose tissue as 
well as increased sympathetic nerve activity and norepinephrine turnover. The 
key element is a mitrochondrial transport protein called Uncoupling Protein-1 
(UCP-1) which causes uncoupling of respiration from oxidative 
phosphorylation without ATP synthesis. Leptin by increasing gene expression 
of UCP-1 in brown adipose tissue increases energy expenditure63.  
d. Action on central nervous system 
It acts as a modulator of appetite via a number of hypothalamic 
mediators. Leptin decreases the level of mRNA for Neuropeptide Y (NPY) in 
the arcuate nucleus. It also increases the level of mRNA for an inhibitor of food 
intake corticotrophin releasing hormone in the paraventricular nucleus64. 
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An intracerebroventricular injection of leptin increases the activity of 
both lumbar and renal sympathetic nerve activity and reduces arterial blood 
flow to skeletal muscle. Leptin also penetrates the blood-cerebrospinal fluid 
barrier by active transport and activates sympathetic nerve activity in the 
central nervous system. Leptin binding sites have been found in regions of the 
brain that are also important in cardiovascular control, hence there is reason to 
believe that leptin could affect cardiovascular function through its effect on the 
central nervous system. 
e. Regulation of insulin and glucose homeostasis 
Leptin markedly decreases plasma insulin concentration and modestly 
reduces blood glucose. The mechanisms are not clear yet. A recent study by 
Kieffer et al indicates that there are leptin receptors located on the pancreatic β 
cells, although the function of these receptors are not known65. Leptin may also 
decrease insulin release by stimulating α-adrenergic receptors in the pancreas 
via its effect on sympathetic activity. But the finding that it reduced plasma 
glucose suggests additional effects besides a simple inhibition of insulin 
secretion.  
Another possibility is that leptin increases glucose utilization or 
improved insulin sensitivity in peripheral tissues, which enhances glucose 
disposal in skeletal muscle and fat cell and suppresses glucose output by the 
liver. Thus the decrease in plasma insulin could be a compensatory response to 
a fall in plasma glucose. 
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f. Renal effects 
The kidneys express full length leptin receptor. It can be speculated that 
insulin and leptin interact and modulate each other’s effect on renal sodium 
handling. Insulin infusion causes anti-natriuresis in healthy subjects, whereas 
leptin infusion increases renal, sodium and water excretion via a direct tubular 
action without affecting renal blood flow and glomerular filtration rate66. It can 
be speculated that some of the peripheral actions of leptin such as diuresis and 
natriuresis act as compensatory mechanisms against the potential deleterious 
effects of an increased fat mass. 
Kidneys play an important role in leptin metabolism because leptin is 
removed from the circulation primarily by the kidneys. In renal failure, there is 
reduced renal clearance, which contributes to elevated plasma leptin 
concentration. 
Recent in-vitro studies suggest that leptin could induce proliferation and 
differentiation of haematopoietic stem cells and there might be synergism 
between leptin and erythropoietin67,68. 
g. Effect on cardiovascular system 
Leptin levels cause sustained changes in cardiovascular and 
neurohumoral function. High leptin levels are found to elevate arterial pressure 
and heart rate. Studies have shown that chronic infusion of leptin in rats has 
resulted in elevated arterial pressure and heart rate. A highly polymorphic 
tetranucleotide repeat polymorphism in the 3’ flanking region of the leptin gene 
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has been identified11. This polymorphism is associated with hypertension 
independent of obesity.  
There are several mechanisms by which leptin increases the arterial 
pressure 
1. One possible explanation is through sympathetic activation. 
Leptin administered intravenously, intracerebroventricularly and 
into hypothalamic nuclei in rodents has been found to increase 
the sympathetic outflow to the kidneys, adipose tissue and the 
skeletal muscle vasculature and the neural traffic to the adrenals8. 
2. It has also been reported that leptin induces endothelin-1, a potent 
vasoconstrictor and mitogen which causes vasoconstriction of 
glomerular afferent and efferent arterioles which leads to 
decreased renal plasma flow and GFR21. 
3. It also contributes to hypertension via its effects on tubular 
sodium handling23. 
4. It also promotes angiogenesis, which contributes to the 
modulation of endothelial cell proliferation in atherosclerosis22. 
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AIM OF THE STUDY 
On reviewing the physiological role of leptin and its association with 
essential hypertension in the elderly patients, the study has been taken up with 
the keen interest to establish the following aims: 
* To determine the reference ranges for the study for the following 
parameters: fasting plasma glucose, serum urea and creatinine, 
lipid profile including serum triglycerides (TGL), total 
cholesterol (TC), HDL-C and LDL-C. 
* To determine the reference range of serum leptin levels for the 
study. 
* To determine the level of serum leptin levels in subjects with 
essential hypertension. 
* To analyze whether the leptin levels in essential hypertension 
varied from the above range. 
* To analyze the level of lipid parameters in patients with essential 
hypertension and to determine whether there is any significant 
change of its level from that of apparently healthy controls. 
* To analyze the body mass index and waist hip ratio in patients 
with essential hypertension and to determine whether there is any 
significant change in the ratio from that of apparently healthy 
controls.  
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MATERIALS AND METHODS 
The study was carried out during the period Jan 2007-April 2007. It was 
done in 2 groups, namely, apparently healthy controls and subjects with 
essential hypertension in the elderly males (> 60 years). 
Control group 
The group comprised of 39 apparently healthy elderly male subjects 
with no significant medical illness. They were selected from the patients 
attending the outpatient department (OPD) of Geriatrics, Madras Medical 
College, Chennai 
Test group 
 This group comprised of elderly males with essential hypertension and 
were attending the OPD of Geriatrics, Madras Medical College, Chennai. 
Based on the following inclusion and exclusion criteria males of this group 
were selected. 
Inclusion criteria 
  Patients with confirmed diagnosis of essential hypertension based on 
history and blood pressure measurement using sphygmomanometer. 
Exclusion criteria 
* Patients of essential hypertension with associated diabetes mellitus 
   
30
* Patients of essential hypertension without any h/o coronary artery 
disease and any other medical illness. 
* Patients of essential hypertension with high body mass index. 
Sample collection 
6 ml of peripheral venous blood was withdrawn from all the study 
subjects under sterile conditions with disposable syringes after overnight 
fasting. One ml of blood was transferred into the test tube containing a pinch of 
potassium oxalate and sodium fluoride (3:1 mixture) for plasma glucose 
estimation. The remaining 5 ml of blood was transferred to a plain tube. 
 Serum separated from this tube was pipetted into a centrifuge tube and 
was centrifuged at 2500 revolutions per minute for 5 minutes, to get clear 
serum without any cells.1 ml of the above serum was stored at –20°C for the 
estimation of serum leptin. From the remaining serum, parameters such as 
Urea, Creatinine, serum triglycerides, total cholesterol, HDL and liver function 
tests were measured within 6 hours of blood collection by enzymatic methods 
using commercial kits. Height (in cms) and Weight (in kgs) of the subjects 
were measured to calculate the body mass index. Waist and hip circumference 
were measured to calculate waist/ hip ratio. 
 The biochemical parameters undertaken for the study were determined 
using the following methodologies:  
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ESTIMATION OF SERUM LEPTIN LEVELS – ELISA METHOD 
Samples 
In the present study serum samples were stored at -20oc and analysed 
within 3 months. 
Available methods 
 Earlier assays were semi quantitative based on immunoprecipitation. 
Western blot technique uses an immunopurified biotinylated primary antibody 
raised by immunizing rabbit with a peptide corresponding to the first 20 amino 
acids of leptin. The first commercial assay was produced in 1996 by Linco 
Research Inc., Missouri, OSA as detailed by Ma et al. 
 The Linco assay utilizes I125 labeled human recombinant leptin, human 
recombinant calibrators and an antiserum raised by immunizing rabbits with 
highly purified recombinant human leptin. By this kit, leptin level can be 
measured in serum, plasma, cerebrospinal fluid, tissue culture media. 
 Enzyme Linked Immuno Sorbent Assay (ELISA) is also available. 
HUMAN LEPTIN ASSAY BY ELISA 
Principle 
 It is a solid phase Enzyme Linked Immuno Sorbent Assay (ELISA) 
based on the sandwich principle. 
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 The microtiter wells are coated with a monoclonal antibody directed 
towards a unique antigenic site on a leptin molecule. An aliquot of patient 
sample containing endogenous leptin is incubated in the coated well with a 
specific rabbit anti-leptin antibody. A sandwich complex is formed. After 
incubation the unbound material is washed off and an anti rabbit peroxidase 
conjugate is added for detection of the bound leptin. 
 Having added the substrate solution, the intensity of colour developed is 
proportional to the concentration of leptin in the patient sample 
Reagents 
 Human leptin ELISA kit was procured from DRG Instruments GmbH, 
Germany. Each kit has 96 microtiter wells and contains the following reagents. 
1. Microtiter wells 12*8 (break apart) strips, 96 wells; Wells coated 
with antileptin antibody (monoclonal) 
2. Standard (0-5), 6 vials, 200 µl, ready to use; contains 0.3% 
Proclin as a preservative. 
3. Control, 2 vials, 200 µl, ready to use; 2 levels (low and high) 
contain 0.3 % Proclin as a preservative. 
4. Assay buffer, 1 vial, 11 ml, ready to use; contains 0.3% Proclin 
as a preservative 
5. Antiserum, 1 vial, 11 ml, ready to use; Polyclonal leptin 
antiserum, contains 0.3% Proclin as a preservative. 
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6. Enzyme complex, 1 vial, 11 ml, ready to use; Anti rabbit 
complex conjugated to horseradish peroxidase, contains < 0.3% 
proclin as a preservative. 
7. Substrate solution, 1 vial, 11 ml, ready to use 
8. Stop solution, 1 vial, 6ml, ready to use, contains 0.5 M H2SO4 
9. Wash solution, Qty: 30ml/vial (40 x concentrated) 
Preparation: 30 ml of concentrated wash solution is 
diluted with 1170ml deionized water to a final 
volume of 1200ml. 
Storage and Stability 
All reagents and kits were refrigerated at 2-8 oc. 
Assay procedure 
Step 1: The desired number of microtitre wells was secured in the 
holder. 
Step 2 : Using new disposable tips, 15µl of each standard, controls 
and samples were dispensed into appropriate wells. 
Step 3 : 100µl Assay buffer was dispensed into each well. 
Step 4 : Complete mixing was done for 10 seconds. 
Step 5 : The plate was then incubated at room temperature for 120 
minutes. 
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Step 6 : The contents of the wells were briskly shaked out followed 
by rinsing of wells 3 times with diluted wash solution 
(300µl per well). The wells were striked well on adsorbent 
paper to remove residual droplets. 
Step 7 : Then 100µl of antiserum was added to each well and 
allowed to incubate for 30 minutes at room temperature. 
Step 8 : The contents of the wells were briskly shaked out followed 
by rinsing of wells 3 times with diluted wash solution 
(300µl per well). The wells were striked well on adsorbent 
paper to remove residual droplets. 
Step 9 : Then 100µl enzyme complex was added into each well 
and allowed to incubate for 30 minutes at room 
temperature. 
Step 10 : The wells were then rinsed 3 times with wash solution 
(300µl per well) and residual droplets were removed with 
adsorbent paper. 
Step 11 : Then 100µl of substrate solution was added to each well 
and allowed to incubate for 15 minutes at room 
temperature. 
Step 12 : The enzymatic reaction was then stopped by adding 50µl 
of stop solution to each well. 
Step 13 : The OD was read at 450±nm with a microtitre plate reader 
within 10 minutes after adding stop solution. 
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Calculation of Results 
1. The average absorbance values for each set of standards, controls 
and patient samples were calculated. 
2. A standard curve was constructed by plotting the mean 
absorbents obtained from each standard against its concentration 
with absorbance value on the vertical (Y) axis and concentration 
on the horizontal (X) axis. 
3. Using the mean absorbance value for each sample, the 
corresponding concentration was determined from the standard 
curve. 
Normal value 
Males  – 3.84 + 1.79 
Females  – 7.36 + 3.73 
Assay characteristics 
Assay Dynamic Range 
The range of the assay is between 0-100ng/ml 
Cross Reactivity 
         The assay had no detectable cross reactivity with Human Insulin, Human 
Proinsulin, Human C-Peptide, Glucagon and IGF-1. 
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Analytical Sensitivity 
          The analytical sensitivity was calculated from the mean plus two 
standard deviations of twenty replicate analysis of Standard 0 and was found to 
be 1.0ng/ml. 
Estimation of Plasma Glucose 
Method : Glucose oxidase peroxidase (GOD/POD) 
Kit Used :  Autopak of Bayer Diagnostics 
Principle  
         Glucose Oxidase 
 Glucose + O2     Gluconic acid + H2O2 
 
        Peroxidase  
H2O2 + Phenolic compound            Pink coloured compound + 
+4 aminoantipyrine          2H2O (Quinonemine)  
    
The intensity of pink coloured compound is proportional to glucose 
concentration and was measured at 505nm. 
Reagents 
1. Glucose reagent – Consists of glucose oxidase, peroxidase, 
4aminoantipyrine, 4hydroxy benzoic acid and phosphate buffer 
2. Glucose standard - 100mg/dl 
Reagent reconstitution 
Working solution was prepared by dissolving one tablet of glucose 
reagent in 20ml of deionised water with continuous stirring. It was stored in 
brown bottle. 
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Procedure 
To 1ml of working solution, 10µl of plasma was added and incubated at 
37oc for 15 mins and absorbance was measured at 505. 
Reference range 
Fasting plasma glucose –> 70 –100 mg/dl 
Estimation of BUN 
Method  : UV method 
Kit used  : Autopak  of Bayer Diagnostics 
Principle   
Urea is hydrolysed in the presence of water and urease to produce 
ammonia and carbon dioxide. The ammonia produced combines with α-
ketoglutarate and NADH in the presence of glutamate dehydrogenase to yield 
glutamate and NAD. The amount of urea nitrogen may be calculated by 
determining the absorbance decrease per minute relative to urea nitrogen 
standard at 340nm. 
Reagents  
Reagent 1(Enzymes) 
  ADP   0.66M mol/L 
  GLDH  > 1000U/L 
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  Urease  > 30000U/L      
  NADH  0.32mmol/L 
  α-Ketoglutarate 9 mmol/L 
Reagent 1A(Buffer) 
  Tris buffer, pH 7.55  75mmol/L 
Standard(BUN 20 mg/dl) 
  Urea   0.428g/L 
Reagent reconstitution 
 Reagents were allowed to attain room temperature. One bottle of reagent 
1 was mixed with one bottle of reagent 1A and mixed by gentle swirling. 
Procedure 
To 1 ml of the reconstituted reagent 10µl of serum is added and read 
immediately  at 340 nm. 
Reference Range 
Serum / plasma : 5-25 mg/dl 
Estimation of Serum Creatinine 
Method    : Picrate method 
Kit used   :  Autopak of Bayer Diagnostics 
Principle  
 Creatinine in alkaline solution reacts with picrate to form a red- orange 
compound. The colour is proportional to the concentration of creatinine in the 
sample when measured at 500nm. 
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Reagents 
Reagent 1 (Picrate) 
  Picric acid   34.9mmol/L 
  Sodium hydroxide 45mmol/L 
 Reagent 2 (Sodium hydroxide) 
  Sodium hydroxide 0.26mol/L 
 Standard (Creatinine 2 mg/dl) 
  Creatinine  0.020 g/L 
Reagent Reconstitution 
 Allow the reagents to attain room temperature. Mix equal volumes of 
reagent 1 and reagent 2 in a clean beaker. 
Procedure 
 To 1ml of the reconstituted reagent 100µl of the serum is added and read 
immediately. 
Reference Values 
   Males  : 0.6-1.1mg/dl 
  Females : 0.5-0.9 mg/dl      
Estimation of Serum triglyceride 
Method : Enzymatic colorimetric method. 
Kit used : Autopak of Bayer Diagnostics 
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Principle 
         Lipoprotein Lipase 
Triglyceride + H2O       Glycerol + Fatty acid 
    Glycerol Kinase 
Glycerol + ATP   Glycerol-3-Phosphate  
               +ADP 
    Glycerol-3-Phosphate 
    Oxidase 
 Glycerol-3-Phosphate + O2     Dihydroxy acetone phosphate  
+ H2O2 
                Peroxidase 
 2 H2O2 + 4Aminoantipyrine + ADPS    Red Quinone + H2O 
 
The intensity of purple coloured complex formed during the reaction is 
directly proportional to the triglyceride concentration in the sample and is 
measured at 546nm. 
Reagents 
 Reagent 1 (Enzymes / Chromogen) 
 Lipoprotein lipase   > 1100 U/L 
 Glycerol kinase   > 800 U/L 
 Glycerol-3-Phosphate Oxidase > 5000 U/L 
 Peroxidase    > 350 U/L 
 4-Aminoantipyrine   0.7 mmol/L 
 ATP     0.3 mmol/L 
Reagent 1A (Buffer) 
Pipes buffer, pH 7.50  50 mmol/L 
ADPS     1 mmol/L 
Magnesium salt   15 mmol/L 
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Standard (Triglycerides 200 mg/dl) 
Glycerol (Trig. equivalent)  2 g/L 
Reagent Reconstitution 
 Reagents were brought to room temperature. Contents of one bottle of 
reagent 1 were dissolved with one bottle of reagent 1A. It was mixed gently by 
swirling. 
Procedure 
 To 1 ml of the reconstituted reagent 10µl of serum is added and read at 
546 nm after incubation at 37oc for 5 min.      
Reference range 
Males  : 60-165 mg/dl 
Females : 40-140 mg/dl 
Estimation of Serum Total Cholesterol 
Method : Cholesterol Esterase – Cholesterol Oxidase 
Kit used : Autospan of Span Diagnostics Ltd 
Principle 
 Cholesterol Esterase 
Cholesterol Ester + H2O      Cholesterol + Fatty  
acids 
    Cholesterol Oxidase 
 Cholesterol + O2       Cholestenone + H2O2 
          
        Peroxidase 
 H2O2 + Phenol + 4-Aminoantipyrine     Red quinone + 4H2O 
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 The concentration of cholesterol in the sample is directly proportional to 
the intensity of the red complex (Red Quinone), which is measured at 500 nm. 
Reagents 
 Reagent 1 (Enzymes / Chromogen) 
 Cholesterol Esterase   > 200 U/L 
 Cholesterol Oxidase   > 250 U/L 
 Peroxidase    > 1000 U/L 
 4-Aminoantipyrine   0.5 mmol/L 
Reagent 1A (Buffer) 
Pipes buffer, pH 6.90   50 mmol/L 
Phenol     25 mmol/L 
Sodium Cholate    0.5 mmol/L 
Standard (Cholesterol 200 mg/dl) 
Cholesterol     2 g/L 
Procedure 
 To 1ml of the reconstituted reagent, 10µl of serum was added and 
reading was taken after 5 mins of incubation at 37 oc.  
Reference values 
 Cholesterol : 150-260 mg/dl 
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Estimation of HDL Cholesterol 
Method :     Phosphotungstate method 
Kit Used :    Autopak of Bayer Diagnostics 
Principle: 
 Chylomicrons, VLDL (Very Low Density Lipoprotein) and LDL 
fractions in serum or plasma are separated  from HDL by precipitating with 
phosphotungstic acid and magnesium chloride. After centrifugation, the 
cholesterol in the HDL fraction, which remains in the supernatant is assayed 
with enzymatic cholesterol method, using cholesterol esterase, cholesterol 
oxidase, peroxidase and the chromogen 4-aminoantipyrine/ Phenol. 
Reagents 
Reagent 1(Enzymes/ Chromogens) 
Cholesterol esterase   > 200U/L 
Cholesterol oxidase   > 250U/L 
Peroxidase     > 1000U/L 
4-Aminoantipyrine               0.5 mmol/L 
Reagent 1A (Buffer) 
Pipes buffer, pH 6.90  50 mmol/L 
Phenol    24 mmol/L 
Sodium Cholate   0.5 mmol/L 
Reagent 2(Precipitating Reagent):  
Phosphotungstic acid  2.4 mmol/L 
Magnesium Chloride            39 mmol/L 
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Standard (HDL Cholesterol 50 mg/dl) 
Cholesterol    0.5 g/L  
Procedure 
1. Precipitation 
200µl of serum was added to 200µl of Precipitating reagent 2 and was 
centrifuged at 1500g or 3500-4000 rpm for 10 min. 
Clear supernatant was immediately separated and cholesterol content was 
determined as follows: 
2. Cholesterol Assay: 
To 1 ml of Reconstituted Reagent , 20µl of the supernatant was added 
and reading was taken after 5 min of incubation at 37 oc. 
Reference values 
Serum HDL-C  :   30-70 mg/dl 
VLDL AND LDL Cholesterol 
These parameters were calculated using Friedwald’s formula given 
below 
  LDL-c       =   TC- (HDL-c+VLDL-c) 
  VLDL-c    =   TGL/5 
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RESULTS 
The estimated levels of various biochemical parameters namely fasting 
plasma glucose, serum urea, serum creatinine, serum triglycerides, serum total 
cholesterol, serum HDL, calculated LDL and serum leptin levels of all the 
subjects selected for the study irrespective of the grouping are tabulated in 
Master Table No 2, along with calculated BMI, WHR, exposure to smoking 
and alcohol all of which are risk factors for essential hypertension. Of the 
selected subjects, S.No 1- 39 in the Master Table consists of the control 
subjects and S.No 40-89 consists of elderly males with essential hypertension. 
Table No 3 gives the compilation of the levels of biochemical and 
physical parameters in apparently healthy controls (i.e S.No 1-39 in Table 2). 
The mean and standard deviation for each parameter is also given in the table. 
 Table No 4 depicts the compilation of biochemical and physical 
parameters in the hypertensive subjects (i.e S.No 40-89 in Table 2). The mean 
and standard deviation of each parameter is also shown in the table. The mean 
levels of each blood parameter in the two groups are also shown as bar 
diagrams in Figures 7-15.  
 To determine how far the levels of biochemical and physical parameters 
varied between the two groups, the mean levels in controls were compared 
with that of the hypertensive subjects, which is depicted in Table No 5. The 
statistical significance was determined using the student’s “t” test and Mann-
Whitney test was performed for non-normal distribution. 
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 For the discrete variables, such as smoking and alcohol, significance 
was determined using chi-square test as shown in Table 6 & 7. Association of 
smoking and alcohol with hypertension was not found. 
From the Table 5, it is evident that elderly subjects with high blood 
pressure had significantly high BMI and leptin levels than healthy controls. 
 To adjust for the effect of BMI on leptin levels, both the groups were 
subdivided into three categories – BMI < 19, BMI 19-21, BMI > 21. 
 Tables 8-10 shows the compilation of biochemical parameters in 
controls with BMI < 19, 19-21 & >21 respectively. The mean and standard 
deviation for each parameter is also shown in the tables.  
 Tables 11-13 shows the compilation of biochemical parameters in 
hypertensive subjects with BMI < 19, 19-21 & > 21 respectively. The mean 
and standard deviation for each parameter is also shown. 
 Table No 14 shows comparison of biochemical parameters between the 
controls and hypertensives with BMI <19. The statistical significance was 
determined using t test. Of all the parameters, only serum leptin level was 
significant with p value < 0.05. 
 Table No 15 shows comparison of biochemical parameters between the 
controls and hypertensives with BMI 19-21. The statistical significance was 
determined using t test. Between the 2 groups, only serum leptin level was 
significant with p value < 0.05. 
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 Table No 16 shows comparison of biochemical parameters between the 
controls and hypertensives with BMI >21. The statistical significance was 
determined using t test. It is evident from the table that leptin levels differed 
significantly between the 2 groups with p value < 0.05. 
    Table No 17 shows the results of a univariate logistic regression to 
analyze the effect of various physical and biochemical parameters as risk 
factors for the development of hypertension in the elderly. It is evident from 
the table that hyperleptinaemia and BMI are positively associated with high 
blood pressure, whereas other parameters such as smoking, alcohol, WHR and 
lipid profile are not associated with high blood pressure. 
Table No 18 shows the results of multivariate regression analysis 
performed after adjusting for leptin in case of BMI and by adjusting BMI in 
case of leptin.  Only leptin was found to be significantly associated with high 
blood pressure. The association of BMI and leptin with systolic and diastolic 
blood pressure is also depicted as bar diagrams in Figures 16 & 17. 
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DISCUSSION 
Analysis of the results obtained in the study starts with scrutinizing the 
reference range obtained. 
 The reference ranges of the relevant biochemical and physical 
parameters of the apparently healthy controls are given below: 
Fasting Plasma Glucose = 81 ± 10.56 
 Serum Urea   = 23.2 ± 7.73 
 Serum Creatinine  = 0.98 ± 0.17 
 Serum Triglycerides  = 111.2 ± 49.61 
 Total Cholesterol  = 154.4 ± 32.68 
 Serum HDL   = 38.5 ± 4.53 
 Serum LDL   = 93.6 ± 33.6 
 Body Mass Index  = 19.63 ± 2.04 
 Waist Hip Ratio  = 0.95 ± 0.05 
 The reference ranges for the various biochemical parameters quoted 
above for controls are acceptable as they fall within the reference ranges 
quoted in the methodology adopted for their analysis.  
 The reference range for serum leptin levels in healthy controls is 3.17 ± 
2.84, which is well within the levels given in the kit methodology. 
 Hence the mean levels of the analysed biochemical parameters obtained 
from apparently normal geriatric individuals are accepted as valid reference 
range for the study. 
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 On scrutinising Table 5, where the mean levels of the biochemical 
parameters in cases are compared with the reference range obtained in the 
study, it is found that among the analysed parameters, serum leptin levels, BMI 
and blood pressure are significantly higher in the cases (p< 0.000 for leptin and 
< 0.05 for BMI). 
 The association of high BMI with elevated blood pressure obtained in 
the study is consistent with the results obtained in various studies. There are 
several potential mechanisms linking this association. They are: 
* By activation of sympathetic nervous system and rennin-
angiotensin-aldosterone system69,70. 
* Increased fatty acid produced in obese patients stimulates 
aldosterone production independent of renin71. 
* Obesity causes insulin resistance and hyperinsulinemia which 
leads to hypertension by increasing sodium reabsorption directly, 
by enhancing sympathetic activity or by increasing 
responsiveness to angiotensin II in the secretion of aldosterone72. 
Also the association of high leptin levels with hypertension in the cases 
is consistent with the results from various studies. Several studies suggest the 
role of leptin in the pathogenesis of hypertension. In animal studies, leptin is 
found to increase sympathetic nervous activity to the kidneys, hindlimb and 
adrenal glands20. Chronic infusion of leptin in conscious rats was found to 
increase arterial pressure and heart rate9. Leptin deficient ob/ob mice have low 
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arterial pressure, suggesting a critical role for leptin in maintenance of arterial 
pressure73. 
Despite some studies showing a natriuretic effect of leptin, leptin 
appears to elevate blood pressure without increasing natriuresis, thereby 
adversely shifting the pressure-natriuresis curve74. Thus increased renal 
sympathetic activity combined with decreased natriuresis is likely to produce 
hypertension75. 
Leptin has also been shown to stimulate endothelial nitric oxide release 
and cause coronary vasodilatation. However, only sympathectomised rats have 
a depressor response to leptin, which suggests that leptin-induced sympatho-
excitation opposes the direct vasodilatory effect of leptin invivo76. Thus given 
the strong association of leptin and hypertension demonstrated by multiple 
studies, the invivo vasodilation effects seem to be minimal compared to its 
sympathetic pressor effects. 
 In this study, both BMI and leptin levels were found to be associated 
with hypertension. To check whether the high leptin levels in the cases is 
independent of the high mean BMI of the cases, it was decided to categorise 
the controls and cases into three groups based on their BMI, namely “<19”, 
“19 to 21” and “>21”. 
It was found that in all the three groups leptin was significantly 
associated with hypertension independent of BMI implying a strong 
association. Further, a multivariate regression analysis was done adjusting 
leptin for BMI and BMI in case of leptin. Only Leptin was significantly 
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associated with hypertension whereas the difference in BMI between the two 
groups was not significant when adjusted for leptin levels. 
The high levels of leptin in the cases might have predisposed these 
individuals to develop hypertension. Increased activation of sympathetic 
nervous system combined with decreased natriuresis by high levels of 
circulating leptin is likely to produce hypertension. 
The cause for high leptin levels observed in the cases could be due to  
1. Polymorphism in the leptin gene. Shintani et al11 has 
demonstrated a highly polymorphic tetranucleotide repeat 
polymorphism in the 3’ flanking region of the leptin gene, thus 
indicating a genetic association of leptin with hypertension, 
independent of obesity. 
2. Polymorphism in the leptin receptor gene77. 
3. Defect in leptin signal transduction in leptin-expressing neurons 
in the hypothalamus, thus leading to hyperleptinemia78. Since the 
peripheral actions are preserved, it contributes to the 
development of hypertension via the mechanisms discussed 
above. 
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SUMMARY  
Hypertension is one of the common diseases afflicting humans. Because 
of the associated morbidity, mortality and cost to the society, it is an important 
public health challenge. 
Aging is associated with a metabolic decline characterised by the 
development of changes in fat distribution, obesity and insulin resistance. All 
these alterations are associated with a variety of age-related diseases such as 
hypertension, atherosclerosis and stroke.   
It is well recognised that an increased body weight is often associated 
with metabolic disorders as well as increased blood pressure. Indeed, obesity 
activates the sympathetic nervous and renin-angiotensin system, all of which 
have been thought to raise blood pressure.  
Recently, a possible role of leptin, a peptide hormone secreted from 
adipose tissue and involved in the regulation of food intake and satiety, has 
been implicated in modulating many of these metabolic alterations. Human 
obesity is characterised by elevated plasma leptin levels and resistance to the 
metabolic effects of the hormone. The high leptin levels cause increased 
sympathetic activity in the circulation and at the renal level leading to the 
development of hypertension. 
There is a strong inter-relation between leptin, BMI and other measures 
of body fat, which has made it difficult to investigate the influence of this 
peptide on blood pressure. Hence the present study was undertaken to establish 
the role of leptin in the pathogenesis of hypertension and whether the 
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association is independent of the level of BMI, body fat distribution and age, as 
all these factors are, in turn, positively associated with blood pressure.  
The study population comprised of 50 elderly hypertensives and 39 
elderly healthy controls. The study included physical examination, 
anthropometric measurements, blood test, medical history, dietary, drinking 
and smoking habits. 
Serum leptin levels were determined using ELISA. Statistical analysis 
was performed using student’s t-Test to detect the association between the 
selected variables. Multivariate logistic regression was used to determine the 
role of leptin as a predictor of blood pressure accounting for potential 
confounders. 
It was observed that the serum leptin levels were significantly elevated 
in the hypertensives compared to the normotensives. The elevated levels of 
leptin could be due to polymorphism in the leptin gene, its receptor or any 
alteration in the leptin signaling pathways. The circulating high leptin levels 
cause increased sympathetic nerve activity and higher plasma levels of 
adrenaline and nor-adrenaline thus contributing to hypertension. 
In this study it was observed that hyperleptinaemia was a significant risk 
factor for high blood pressure for elderly individuals independent of BMI. This 
functional data on the direct effect of leptin on blood pressure suggests that the 
leptin gene and its product, leptin are an attractive target for studies on the 
mechanism of hypertension and for the development of methods for the 
prediction, prevention and treatment of hypertension. 
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CONCLUSION 
From the discussion held on the results obtained in the study on leptin, 
the following conclusion is arrived at regarding the biochemical parameters: 
* The serum leptin levels in the control group is 3.17 ± 2.85 which 
is the reference range for the study. 
* Serum leptin levels are significantly elevated in the essential 
hypertensive cases above the reference range (11.1 ± 7.6) 
indicating hyperleptinaemia in this group. 
* There is no significant change in the levels of lipid parameters 
between the controls and hypertensive cases in the study. 
* The various physical parameters such as BMI and WHR does not 
seem to significantly correlate with elevated blood pressure. 
* There is a significant relationship between plasma leptin levels 
and blood pressure independent of potential confounders. 
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SCOPE FOR FURTHER STUDY 
* Further studies are needed to determine the precise role of CNS and 
peripheral effects of leptin in long term blood pressure regulation. 
* Studies are needed to investigate whether leptin upregulates the activity 
of AGT gene and thus contributes to hypertension. 
* Studies analyzing the mechanism of leptin receptor signaling  by  
SOCS-3. 
* Further studies on polymorphism in the regulatory region of the leptin 
gene to determine whether the association of leptin with hypertension is 
primary or secondary. 
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LEPTIN RECEPTOR (OB - R) ISOFORMS AND KNOWN 
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LEPTIN SIGNALING 
 
 
 
 
 
 
 
 
 
Courtesy : Malaka et al, 2006 
  
FIGURE - 6 
LEPTIN ACTION DOWNSTREAM 
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Serum Leptin Levels in Control & Hypertensive 
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Dia BP in Control & Hypertensive cases
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FIGURE - 10 
BMI in Control & Hypertensive cases
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FIGURE - 11 
WHR in Control & Hypertensive cases
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FIGURE - 12 
TGL in Control & Hypertensive cases
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
Control Hypertensives
Control Hypertensives
 
FIGURE - 13 
Cholesterol in Control & Hypertensive cases
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HDL in Control & Hypertensive cases
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FIGURE - 16 
Leptin with systolic and diastolic blood pressure
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BMI with systolic and diastolic blood pressure
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